D(
Therapeutic Areas
Ipca Laboratories Pipeline
| Drug | Indication | Phase |
|---|---|---|
| ANDA Portfolio (Generic Drugs) | Various (Cardiovascular, CNS, Anti-infectives) | Approved / Filed |
| Zerodol range (Aceclofenac) | Pain & Inflammation | Commercial |
| Hydroxychloroquine Sulfate | Malaria, Lupus, Rheumatoid Arthritis | Commercial |
| Chloroquine Phosphate | Malaria | Commercial |
| Metformin & Combinations | Type 2 Diabetes | Commercial |
| Cefixime & Ofloxacin combinations | Bacterial Infections | Commercial |
| Biosimilar (Rituximab) | Oncology, Autoimmune Diseases | Development |
| Biosimilar (Bevacizumab) | Oncology | Development |
Leadership Team at Ipca Laboratories
PG
Premchand Godha
Founder & Chairman Emeritus
AK
A. K. Jain
Managing Director
AK
Ajit Kumar Jain
Joint Managing Director
AR
Anand R. Desai
Whole-time Director
RC
R. C. Mehta
Whole-time Director
RV
R. V. Easwar
Independent Director
NH
N. H. Atthreya
Independent Director
RA
R. A. Shah
Independent Director
RK
R. K. Jain
Chief Financial Officer
AK
Atul K. Shah
President, International Business